We have assessed the efficacy of a novel bioadhesive amethocaine patch device, compared to Ametop™ gel, in a randomized, double-blinded trial. Patch and gel formulations, including placebos, were applied to the forearms of volunteers (nϭ30) for 40 min. Once the formulations were removed from the skin, anaesthesia was assessed by volunteers using a conventional pinprick test. Pain scores were recorded for 4 h after removal of gels and patches. Statistical analysis of the results indicated that both amethocaine gel and patch preparations were superior to placebo (PϽ0.05). No significant difference was observed between amethocaine gel and patch formulations (PϾ0.05) in either onset time or duration of action for percutaneous local anaesthesia. The results of this study indicate therefore that the novel bioadhesive patch provides clinically comparable anaesthesia to the established gel formulation in a more defined dosage form.
There are two products available in the UK for provision tions. However, the film was non-adhesive and was secured of topical anaesthesia, EMLA ® cream and Ametop TM gel. to the skin by means of a pressure-sensitive island dressing, The former is based on a eutectic mixture of the amide which was complex in design and difficult to make. local anaesthetics lidocaine and prilocaine (2.5% w/w of The formulation and characterization of an integrated, each anaesthetic), while Ametop TM contains 4% w/w moisture-activated, bioadhesive amethocaine patch for amethocaine in a hydrophilic gel. Several clinical studies percutaneous local anaesthesia has been recently reported. 9 have recently compared the efficacy of EMLA ® and While this device also employs the amethocaine phaseAmetop TM , indicating that Ametop TM gel provides a change system, it does not require further surrounding more rapid onset time and a greater duration of anaesthesia adhesive dressings, as it is formulated to incorporate a than EMLA ® cream. [1] [2] [3] [4] This has been attributed to the use bioadhesive co-polymer. 5 This device is relatively simple of the amethocaine phase-change system by Ametop TM gel. to make and the patch has the advantage of being removed In this system, the water in the gel forms a meta-stable easily from skin by peeling without leaving a residue. hydrate with amethocaine and lowers the melting point
The amethocaine phase-change system has to date of the drug from 42°C to~30°C. 5 6 Therefore, when provided the most clinically successful method for delivery Ametop TM gel is applied to intact skin a phase change of percutaneous local anaesthesia. Therefore, the aim of occurs whereby solid particles of amethocaine convert into this study was to evaluate, in a randomized, double-blinded highly penetrative oil globules.
cross-over study, the clinical effectiveness of an integrated, Although gel systems are relatively simple to manufacture water-activated bioadhesive patch device based on the and use, they can be inconvenient in certain situations, for amethocaine phase-change system by comparing it with example, where the mass of gel to be applied is large or the established Ametop TM gel. 5 where a specific region on the skin such as a port-wine stain needs to be treated accurately. 7 The formulation and
Materials and methods
clinical assessment of a hydrophilic amethocaine-containing Bioadhesive amethocaine patches were prepared from gels patch device for percutaneous local anaesthesia has been containing 1% w/w amethocaine, as described previously. 9 previously described. 8 The patch device described produced comparable skin anaesthesia to amethocaine gel formula-Placebo patches were similarly prepared. Both patches Percutaneous local anaesthesia volunteers completed the study. ventral surface of the forearm of the volunteer whereupon a bioadhesive bond was formed. All volunteers received each of the four formulations (active gel and patch, placebo 80.3% of those with a bioadhesive amethocaine patch. Both gel and patch) on four separate occasions. A period of 7 days placebos yielded the maximum pain score of 4. Statistical was observed between administration of formulations. Each analysis using the Fisher exact test indicated that there was formulation was left on the forearm for 40 min. The no significant difference between the placebo gel and patch formulation was then removed and the treated site wiped formulations over the entire time period of the study clean. The volunteers were instructed to prick the site six (PϾ0.05). There was a significant difference (PϽ0.05) times, using a sterile Microlance 25G5/8, in a random between placebo and active formulations. There was no fashion 10 11 and, thereafter, the evoked pain was recorded significant difference (PϾ0.05) between the amethocaine gel on a four-point scale (1 ϭ no pain; 2 ϭ slight sensation; and patch formulations. Table 1 illustrates the distribution of 3 ϭ moderate pain; 4 ϭ no apparent anaesthesia). Pain pain scores 1 and 2 for Ametop TM gel and the amethocaine scores were assessed by each volunteer, at the specified patch (there were no reported pain scores of 3 or 4, for time periods, after patch or gel removal. Pain scores were either active formulation, during the course of the study). recorded and the mean score at each time period was Statistical analyses of the pain scores obtained at each determined. Volunteers were also encouraged to comment time point indicated that there was no significant difference upon any aspect of the dosage form or the trial they desired. (PϾ0.5) between Ametop TM gel and the amethocaine patch.
Data from each volunteer were collated after the trial and analysed by application of a two-way analysis of Discussion variance (ANOVA) with repeated measures. Further analysis was carried out by performing a Fisher exact test for the There are a number of potential advantages in designing a bioadhesive patch device for providing percutaneous local mean. A significance level of 5% was chosen in all tests. 8 9 Pain scores obtained for Ametop TM gel and the ametho-anaesthesia. Each patch will have a specific amount of drug applied to a clearly defined area; this is not possible when caine patch, at each time point, were compared statistically using the chi-square method with a 2 ϫ 2 contingency table using gels or creams. Furthermore, application and removal of the device are potentially easier as gels and creams and employing a continuity correction.
Power was estimated using an approximate two-sample require a covering to protect them from removal from the skin surface. This covering needs to be removed prior to t-test, using the means and standard deviations for the gel and bioadhesive patch at each time point. Overall, the wiping such formulations from the surface of the skin.
Removal of the covering, normally a pressure-sensitive power was estimated at~90% to detect a difference of 1 in the pain scores.
adhesive dressing, can also be quite a painful procedure. Although a previous amethocaine patch device has been described, it was not bioadhesive and required a dressing
Results
to maintain skin contact. The results of the study clearly demonstrated the differAnalysis of variance showed that there was a significant difference between the formulations (PϽ0.05). This was ences between active and placebo formulations. The mean pain scores for both Ametop TM gel and the amethocaine determined, upon further analysis, to be because of the inclusion of the placebo preparations. Analysis of the patch were less than 2 throughout the assessment period, and statistical analyses of the results indicated that there combined pain scores throughout the duration of the selfassessment period showed that with Ametop TM gel 84.4% was no difference in the active preparations. Interestingly, pain scores of 3 and 4 were not reported at any time point of the volunteers had a pain score of 1, compared with and this is in broad agreement with earlier reports on
The results of this study indicate that the water-activated amethocaine patch device produces equivalent anaesthesia amethocaine-based systems.
to the amethocaine aqueous gel formulation. Therefore, The recommended application time for Ametop TM gel is the patch device tested in this study provided a suitable between 30 and 45 min, with the shorter application time alternative to established gel or cream formulations. In being used for children. It has been previously reported addition, it delivers a specific amount of drug to a specific that pain scores of either 1 or 2 are classified as clinically surface area of skin. effective, and hence both active formulations provided satisfactory percutaneous local anaesthesia. 10 The distribu- perhaps, is not surprising given that the drug must first be released from the liposome before it can produce 
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